Drug research

ABX464

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Obefazimod

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1NCT05507203	ABVX	Phase 3	Completed	2025-06-24Actual
Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative ColitisNCT05177835	ABVX	Phase 2	Active not recruiting	2028-03Estimated
Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative ColitisNCT03368118	ABVX	Phase 2	Completed	2022-07-12Actual
Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative ColitisNCT04023396	ABVX	Phase 2	Completed	2023-02-23Actual
ABX464 in Subjects With Moderate to Severe Active Ulcerative ColitisNCT03093259	ABVX	Phase 2	Completed	2018-07-25Actual
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2NCT05507216	ABVX	Phase 3	Completed	2025-06-24Actual
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19NCT04393038	ABVX	Phase 2, Phase 3	Terminated	2021-03-05Actual
Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid ArthritisNCT04049448	ABVX	Phase 2	Completed	2023-01-23Actual
ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor TreatmentNCT02735863	ABVX	Phase 2	Completed	2017-08-30Actual
ABTECT - MaintenanceNCT05535946	ABVX	Phase 3	Active not recruiting	2026-04-28Actual

ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

ABVXCompletedPrimary completion: 2025-06-24 · Actual

Trial details

Registry ID: NCT05507203
Phase: Phase 3

Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

ABVXActive not recruitingPrimary completion: 2028-03 · Estimated

Trial details

Registry ID: NCT05177835
Phase: Phase 2

Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis

ABVXCompletedPrimary completion: 2022-07-12 · Actual

Trial details

Registry ID: NCT03368118
Phase: Phase 2

Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis

ABVXCompletedPrimary completion: 2023-02-23 · Actual

Trial details

Registry ID: NCT04023396
Phase: Phase 2

ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

ABVXCompletedPrimary completion: 2018-07-25 · Actual

Trial details

Registry ID: NCT03093259
Phase: Phase 2

ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

ABVXCompletedPrimary completion: 2025-06-24 · Actual

Trial details

Registry ID: NCT05507216
Phase: Phase 3

ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19

ABVXTerminatedPrimary completion: 2021-03-05 · Actual

Trial details

Registry ID: NCT04393038
Phase: Phase 2, Phase 3

Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis

ABVXCompletedPrimary completion: 2023-01-23 · Actual

Trial details

Registry ID: NCT04049448
Phase: Phase 2

ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment

ABVXCompletedPrimary completion: 2017-08-30 · Actual

Trial details

Registry ID: NCT02735863
Phase: Phase 2

ABTECT - Maintenance

ABVXActive not recruitingPrimary completion: 2026-04-28 · Actual

Trial details

Registry ID: NCT05535946
Phase: Phase 3

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.